Tracked deals
5
5 tracked deals across 2020-2026.
Pharmaceuticals Buyers & Acquisitions in Texas
Buyer mix
Mixed buyer set
7 strategic · 2 family office
Top trend
Volume peaked in 2022
2 tracked deals announced in 2022.
Buyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Alora Pharmaceuticals, LLC | 1 | Parent company of multiple specialty pharmaceutical and p... | Strategic |
| BPGC Management LP | 1 | Independent private equity firm focused on opportunistic ... | PE |
| Bionpharma, Inc. | 1 | Generic pharmaceutical company and supplier of softgel ca... | Strategic |
| Eli Lilly and Company | 1 | Global pharmaceutical company with large clinical develop... | Strategic |
| GMS Capital Partners LLC | 1 | Investment management firm that sources and manages inves... | Family Office |
| Pharma Nobis, LLC | 1 | Newly formed company to own and operate the acquired cont... | Strategic (PE-backed) |
| R Investments | 1 | Merchant banking / investment vehicle wholly owned by Wil... | Family Office |
| Santen Holdings U.S. Inc. | 1 | U.S. subsidiary of Santen focused on commercializing opht... | Strategic |
| Santen Pharmaceutical Co., Ltd. | 1 | Global, publicly listed pharmaceutical company specialize... | Strategic |
| Signet Healthcare Partners | 1 | Growth capital investor focused on commercial-stage healt... | PE |
Acquisition Volume in Pharmaceuticals in Texas by Year
Last 4 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
June 16, 2026
- Buyer
- Eli Lilly and Company
- Target
- 4E Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Texas, United States
- Type
- Buyout
Eli Lilly and Company has acquired Austin-based neuroscience company 4E Therapeutics to advance its non-opioid chronic pain pipeline based on orally available MNK inhibitors. 4E’s lead candidate, 4ET1103, has entered human clinical trials after demonstrating a favorable Phase 1 safety profile.
-
January 5, 2023
- Buyer
- BPGC Management LP, Spinnaker International LLC, R Investments
- Target
- Nurse Assist LLC (Stericare Solutions)
- Industry
- Pharmaceuticals
- Location
- Texas, United States
- Type
- Buyout
BPGC Management LP, Spinnaker International LLC and R Investments acquired a 70% controlling interest in Nurse Assist LLC, the maker of the Stericare Solutions brand, a specialty manufacturer of medical-grade saline and sterile water products. The investor group said it plans to support management to expand the company's in‑house water purification capabilities, broaden product categories and pursue growth initiatives including potential acquisitions.
-
February 4, 2022
- Buyer
- Signet Healthcare Partners, Bionpharma, Inc., GMS Capital Partners LLC, Pharma Nobis, LLC
- Target
- Fagron's U.S. contract manufacturing business and manufacturing facility (Texarkana, Texas)
- Seller
- Fagron
- Industry
- Pharmaceuticals
- Location
- Texas, United States
- Type
- Divestiture
An investor consortium led by Signet Healthcare Partners with Bionpharma, Inc. and GMS Capital Partners formed Pharma Nobis, LLC to acquire Fagron's U.S. contract manufacturing business and manufacturing facility in Texarkana, Texas. Fagron will retain a 20% interest in the new company; Todd Daviau was named CEO and the investors said they will seek to grow the contract manufacturing and private-label capabilities for consumer healthcare and retail customers.
-
January 4, 2022
- Buyer
- Sovereign Pharmaceuticals, LLC, Alora Pharmaceuticals, LLC
- Target
- Monarch PCM, LLC (manufacturing assets, Fort Worth, TX)
- Seller
- Monarch PCM, LLC
- Industry
- Pharmaceuticals
- Location
- Texas, United States
- Type
- Buyout
Alora Pharmaceuticals' wholly owned subsidiary, Sovereign Pharmaceuticals, acquired substantially all manufacturing capabilities of Monarch PCM, LLC in Fort Worth, Texas through bankruptcy proceedings, closing on January 4, 2022. The deal adds 60,000 sq. ft. of manufacturing space and approximately 48 employees, expanding Sovereign's solid, semi-solid and liquid pharmaceutical manufacturing capacity.
-
September 16, 2020
- Buyer
- Santen Holdings U.S. Inc., Santen Pharmaceutical Co., Ltd.
- Target
- Eyevance Pharmaceuticals Holdings Inc.
- Industry
- Pharmaceuticals
- Location
- Texas, United States
- Type
- Buyout
Santen Pharmaceutical Co., Ltd., through its U.S. subsidiary Santen Holdings U.S. Inc., acquired all outstanding shares of Eyevance Pharmaceuticals Holdings Inc. for $225 million in cash. The deal brings Eyevance’s topical ophthalmic product portfolio and U.S. commercial team into Santen’s global ophthalmology business; two development-stage assets (VISOVANQ and NEXAGON) were carved out and excluded from the purchase.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Related Acquisition Pages
Pharmaceuticals Buyers & Acquisitions
Pharmaceuticals Buyers & Acquisitions in Canada
Private Equity-Backed Pharmaceuticals Buyers
Pharmaceuticals Acquisitions in 2026
Pharmaceuticals Acquisitions in 2023
Pharmaceuticals Acquisitions in 2022
Pharmaceuticals Acquisitions in 2020
Acquisitions in Texas
Private Equity-Backed Acquisitions in Texas
Acquisitions in Texas in 2026
Acquisitions in Texas in 2023
Acquisitions in Texas in 2022